Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Thyroid Cancer, Papillary 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solitary Fibrous Tumors 1Solid Tumours 1Sarcoma 1Neoplasm Metastasis 1Mesothelioma 1Melanoma 1Liposarcoma 1Leukemia, Hairy Cell 1Histiocytoma, Malignant Fibrous 1Dermatofibrosarcoma 1Carcinoma 1

Interventions

pembrolizumab 51Carboplatin 21Paclitaxel 20Cyclophosphamide 18Nivolumab 13Taxes 10130-nm albumin-bound paclitaxel 10olaparib 9Specimen Handling 9spartalizumab 8fludarabine 8Doxorubicin 8durvalumab 7Magnetic Resonance Spectroscopy 7Gemcitabine 7Cisplatin 7Biopsy 7veliparib 6atezolizumab 6Fulvestrant 6Albumin-Bound Paclitaxel 6liposomal doxorubicin 5eribulin 5budigalimab 5Irinotecan 5Ipilimumab 5aldesleukin 4Radiotherapy 4Oxaliplatin 4Leucovorin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Triple Negative Breast Neoplasms × Famotidine × Clear all
NCT05035407 2025-12-02

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
36 enrolled 7 charts
Breast

Carcinoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡